Related Experiment Videos

Hypertension and the elderly

J F Potter1

  • 1University Department of Medicine, Glenfield Hospital, Leicester, UK.

Insights

Treating hypertension in elderly patients, especially those with systolic blood pressure over 160 mmHg, significantly reduces cardiovascular risks. Thiazide diuretics and beta-blockers are recommended first-line treatments for this population.

Area of Science:

  • Gerontology
  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease is a leading cause of death in the elderly.
  • Hypertension is the primary treatable risk factor for cardiovascular disease in older adults.
  • There has been a lack of consensus on the assessment and treatment of hypertension in the elderly.

Purpose of the Study:

  • To review the evidence for treating hypertension in elderly patients.
  • To provide guidance on the assessment and management of hypertension in this demographic.
  • To highlight the benefits of antihypertensive therapy in reducing cardiovascular morbidity and mortality.

Main Methods:

  • Review of recent large intervention trials on blood pressure reduction in elderly hypertensive patients.
  • Analysis of data regarding the efficacy of thiazide diuretics and beta-blockers.
  • Consideration of treatment guidelines for elderly patients with specific blood pressure thresholds.

Main Results:

  • Blood pressure reduction in elderly patients with combined and isolated systolic hypertension using thiazide diuretics or beta-blockers significantly reduces cardiovascular morbidity and mortality.
  • The STOP-Hypertension Trial demonstrated a reduction in total mortality with active treatment.
  • Patients under 80 with SBP ≥ 160 mmHg and DBP ≥ 90 mmHg or SBP ≥ 160 mmHg and DBP < 90 mmHg should be considered for antihypertensive therapy.

Conclusions:

  • Negative attitudes towards treating hypertension in the elderly are no longer justifiable.
  • Thiazide diuretics and beta-blockers are established first-line pharmacological therapies.
  • Long-term benefits of other antihypertensive agents require further assessment; benefits in certain subgroups remain unproven.

Related Concept Videos